BioLineRx Ltd.(BLRX)- NASDAQ
  • Mon, Sep. 26, 9:13 AM
    | Mon, Sep. 26, 9:13 AM | 12 Comments
  • Fri, Sep. 23, 12:45 PM
    | Fri, Sep. 23, 12:45 PM | 2 Comments
  • Fri, Sep. 23, 11:01 AM
    | Fri, Sep. 23, 11:01 AM | 4 Comments
  • Fri, Sep. 23, 9:14 AM
    | Fri, Sep. 23, 9:14 AM | 1 Comment
  • Fri, Sep. 23, 8:19 AM
    • Thinly traded nano cap BioLineRx (NASDAQ:BLRX) is up 18% premarket on increased volume in response to its announcement that it has signed an exclusive, worldwide agreement with BGN Technologies and Hadasit for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH). This novel treatment, to be named BL-1220, is the second project in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
    • BL-1220 is an orally administered, novel composition of sodium alginate. Pre-clinical results obtained in animal models of liver impairment suggest that BL-1220 has strong hepato-protective effects. Collectively, the data demonstrate that BL-1220 is able to restore liver function. This technology could be directed toward rapid regeneration of normal liver in both acute and chronic conditions of liver injury.
    • In December 2014, BioLineRx and Novartis Pharma AG entered into a multi-year strategic collaboration to facilitate development and commercialization of Israeli-sourced drug candidates. As part of the agreement, Novartis made an equity investment in BioLineRx of $10M.
    | Fri, Sep. 23, 8:19 AM
  • Tue, Sep. 20, 7:05 AM
    • BioLineRx (NASDAQ:BLRX) initiates a Phase 2a study, COMBAT, assessing lead product candidate BL-8040 and Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) for the treatment of metastatic pancreatic adenocarcinoma. The 30-subject open-label, single-arm trial will evaluate the clinical response, safety and tolerability of the combination. The study is being performed under the companies' January immunotherapy collaboration. According to ClinicalTrials.gov, the estimated study completion date is December 2018.
    • BL-8040 is a synthetic peptide that binds to a protein found on the surface of cancer cells called CXCR4, a chemokine receptor that that plays a key role in tumor growth and survival. CXCR4 is overexpressed in more than 70% of human cancers and is associated with a poor prognosis.
    | Tue, Sep. 20, 7:05 AM | 1 Comment
  • Thu, Sep. 8, 7:50 AM
    • Nano cap BioLineRx (NASDAQ:BLRX) is up 5% premarket on increased volume in response to its announcement of results from a Phase 2a clinical trial assessing lead product candidate BL-8040 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). The data were presented yesterday at the 4th Annual Meeting of the Society of Hematologic Oncology in Houston, TX.
    • The study evaluated BL-8040 as monotherapy and in combination with the chemo agent cytarabine. The reported data set was 45 treatment-resistant AML patients.
    • For the combination therapy, the composite complete remission rate (complete remission + complete remission with incomplete blood count recovery) was 38% (n=15/39) in patients receiving two cycles of BL-8040 at 1 mg/kg or higher. The composite complete remission rate was 41% (n=9/22) in the expansion phase of the study at a dose of 1.5 mg/kg. Both rates were superior to the ~20% historical response rate observed with cytarabine alone. Two-thirds of the patients were still alive during the follow-up period of up to 12 months.
    • BL-8040 is a synthetic peptide that binds to a protein found on the surface of cancer cells called CXCR4, a chemokine receptor that that plays a key role in tumor growth and survival. CXCR4 is overexpressed in more than 70% of human cancers and is associated with a poor prognosis.
    | Thu, Sep. 8, 7:50 AM
  • Wed, Sep. 7, 11:45 AM
    • BioLineRx (BLRX +7.6%) and Roche's (OTCQX:RHHBY) Genentech will collaborate in several Phase 1b clinical trials to evaluate the combination of BioLineRx's lead product candidate BL-8040 and TECENTRIQ (atezolizumab) in multiple cancers.
    • Under the terms of the partnership, Genentech will sponsor and conduct several Phase 1b studies in multiple solid cancers. BioLineRx will sponsor and conduct one Phase 1b study in acute myeloid leukemia (AML). All studies will be open-label and single-arm. After the trials are completed, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details are not disclosed.
    • BL-8040 is a synthetic peptide that binds to a protein found on the surface of cancer cells called CXCR4, a chemokine receptor that that plays a key role in tumor growth and survival. CXCR4 is overexpressed in more than 70% of human cancers and is associated with a poor prognosis.
    • Atezolizumab is a PD-L1 antagonist that is designed to block inhibitory T-cell checkpoints thereby allowing cytotoxic T cells to reach the tumor.
    | Wed, Sep. 7, 11:45 AM | 1 Comment
  • Thu, Aug. 25, 10:53 AM
    • BioLineRx (BLRX -0.7%) and Chinese venture capital fund I-Bridge Capital establish a joint venture in China called iPharma which will develop therapeutic candidates originating primarily from BioLineRx.
    • Under the terms of the agreement, each partner will contribute $1M in seed capital. BioLineRx will vet early-stage drug candidates in Israel. The emphasis will be on therapeutic indications of particular interest to Chinese patients. Promising product candidates will be in-licensed by iPharma for further development and commercialization in China and potentially other markets. Once a threshold of in-licensed programs is reached, iPharma plans to raise additional capital from Chinese investors. Each partner is protected from dilution for five years. The first license should be consummated in the next few months.
    • BioLineRx's current pipeline includes candidates for a range of cancers, celiac disease, diabetes and skin lesion removal.
    | Thu, Aug. 25, 10:53 AM
  • Wed, Aug. 24, 11:48 AM
    • Thinly traded nano cap BioLineRx (BLRX +11.5%) shows some life that may signal an end to the extended downtrend that began last summer. Shares are up ~33% since the most recent low of $0.75 on August 5.
    • Complete data from a Phase 2a study evaluating lead product candidate BL-8040 in relapsed/refractory acute myeloid leukemia (AML) will be presented at the Society of Hematologic Oncology annual meeting in Houston, TX, September 7 - 10.
    • BL-8040 is a synthetic peptide that binds to a protein found on the surface of cancer cells called CXCR4, a chemokine receptor that that plays a key role in tumor growth and survival. CXCR4 is overexpressed in more than 70% of human cancers and is associated with a poor prognosis.
    • The company also announced the commercial launch of BL-5010, an OTC topical medication for the nonsurgical removal of skin lesions, in Q2. It will be marketed by Perrigo's Omega Pharma unit.
    | Wed, Aug. 24, 11:48 AM
  • Thu, Aug. 11, 8:41 AM
    • Biolinerx (BLRX) Q2 results: Revenues: $0; R&D Expense: $2.7M (-6.9%); SG&A: $1.1M (-15.4%); Operating Loss: ($3.9M) (+7.1%); Net Loss: ($3.7M) (+22.9%); Loss Per Share: ($0.07) (+22.2%); Quick Assets: $41.8M (-12.4%); CF Ops: ($7.4M) (-4.2%).
    • No guidance given.
    | Thu, Aug. 11, 8:41 AM
  • Thu, Aug. 11, 7:17 AM
    • biolinerx (NASDAQ:BLRX): Q2 EPS of -$0.07 in-line.
    • Cash and cash equivalents of $3.9M
    • Press Release
    | Thu, Aug. 11, 7:17 AM
  • Thu, Aug. 11, 6:50 AM
    • BioLineRx (NASDAQ:BLRX) promotes CFO Philip Serlin to CEO effective October 10. He succeeds Kinneret Savitsky, Ph.D., who will serve as a scientific advisor to the company through March 2017 before departing.
    • The company also promotes Director of Finance and Reporting Mali Zeevi, CPA, to Chief Financial Officer effective October 10.
    | Thu, Aug. 11, 6:50 AM
  • Tue, Jun. 28, 7:57 AM
    • BioLineRx (NASDAQ:BLRX) announces the filing of regulatory submissions required to commence a Phase 2a trial assessing BL-8040, in combination with Merck's (NYSE:MRKKEYTRUDA (pembrolizumab), for the treatment of pancreatic cancer. The study, called COMBAT, is expected to commence in Q3.
    • The 30-subject, open-label, single-arm study is designed to evaluate the clinical response, safety and tolerability of the combination as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity in patients with metastatic pancreatic adenocarcinoma.
    | Tue, Jun. 28, 7:57 AM
  • Tue, May 17, 8:14 AM
    • Biolinerx (BLRX) Q1 results: Revenues: $0; R&D Expense: $2.6M (-18.8%); SG&A: $1.2M (+9.1%); Operating Loss: ($3.8M) (+11.6%); Net Loss: ($3.5M) (+18.6%); Loss Per Share: ($0.06) (+40.0%); Quick Assets: $45M (-5.7%); CF Ops: ($4.2M) (-20.0%).
    • No guidance given.
    | Tue, May 17, 8:14 AM
  • Tue, May 17, 7:18 AM
    • Biolinerx (NASDAQ:BLRX): Q1 EPS of -$0.06 beats by $0.02.
    • Cash and cash equivalents of $4.6M.
    • Press Release
    | Tue, May 17, 7:18 AM | 1 Comment